Medication info
Ducaro Tablet 60/5/10 mg (Pimasartan Potassium, Amlodipine, Rosuvastatin)

Ducaro Tablet 60/5/10 mg (Pimasartan Potassium, Amlodipine, Rosuvastatin)

Prescription medicationTabletOral
Ingredient · strength
Fimasartan Potassium Trihydrate Granules›150mg / 1 tabletAmlodipine Besylate›6.94mg / 1 tabletRosuvastatin Calcium Micronized›10.4mg / 1 tablet
Manufacturer / importer
Boryung Pharmaceutical Co., Ltd.
Appearance
Orange pentagonal film-coated tablet
Packaging
30 tablets/box [10 tablets/PTP*3]
Approval status
Active

MFDS item code 201907895 · Approved 2019.11.13 · Insurance code 641907360

Summary

Main use
Treatment of hypertension; improvement of dyslipidemia; reduction of atherosclerosis progression and cardiovascular disease risk
Who takes it
Adults · Children
Adult dose
Take 1 tablet once daily with water, regardless of meals. If possible, it is recommended to take it at the same time each day (e.g., in the morning). This medicine is for adults only. The dose should be individualized for each patient based on the efficacy and tolerability of the fimasartan/amlodipine combination and rosuvastatin. Patients taking the fimasartan/amlodipine combination together with rosuvastatin as a single-ingredient product may switch to this medicine (a combination product containing the same amounts of each active ingredient) for convenience. Before starting the fimasartan/amlodipine combination, it is recommended that the dose be adjusted using fimasartan. However, if blood pressure is not controlled as described below, switching directly to this medicine may be considered. ㆍ 30/5 mg: For patients whose blood pressure is not adequately controlled with fimasartan 30 mg monotherapy. ㆍ 30/10 mg: For patients whose blood pressure is not adequately controlled with fimasartan 30 mg monotherapy or 30/5 mg. ㆍ 60/5 mg: For patients whose blood pressure is not adequately controlled with fimasartan 60 mg monotherapy. ㆍ 60/10 mg: For patients whose blood pressure is not adequately controlled with fimasartan 60 mg monotherapy or 60/5 mg. Elderly patients No initial dose adjustment is required in elderly patients aged 70 years or younger. In patients aged 75 years or older, amlodipine clearance is reduced; therefore, treatment should be started at a lower dose, and the dose should be increased gradually. Patients with renal impairment No dose adjustment is required in patients with mild or moderate renal impairment (creatinine clearance 30 ~ 80 mL/min). However, in patients with severe renal impairment (creatinine clearance < 30 mL/min), treatment should be initiated with fimasartan 30 mg in this medicine. Patients with hepatic impairment No dose adjustment is required in patients with mild hepatic impairment. This medicine should not be administered to patients with moderate ~ severe hepatic impairment. Primary hypercholesterolemia (type IIa, including heterozygous familial hypercholesterolemia), mixed dyslipidemia (type IIb), primary dysbetalipoproteinemia (type III), and homozygous familial hypercholesterolemia Patients receiving rosuvastatin should follow a standard cholesterol-lowering diet before and during treatment and continue it throughout the treatment period. Rosuvastatin may be taken at any time of day, regardless of meals. The initial dose is 5 mg once daily. If a greater reduction in LDL cholesterol is required, the dose may be adjusted to the maintenance dose. The maintenance dose is 10 mg once daily, which provides adequate control in most patients. The maintenance dose should be adjusted as appropriate at intervals of 4 weeks or more, according to LDL cholesterol levels, treatment goals, and patient response, and may be increased to a maximum of 20 mg daily. Elderly patients: No dose adjustment is required. Patients with renal impairment: No dose adjustment is required in patients with mild or moderate renal impairment. Do not administer to patients with severe renal impairment. Particular caution should be exercised when administering rosuvastatin 20mg to patients with moderate renal impairment. Patients with hepatic impairment: No increase in systemic exposure to rosuvastatin was observed in patients with a Child-Pugh score of 7 or less, but an increase was observed in patients with a Child-Pugh score of 8 or 9. Renal function testing should be considered in these patients. There is no experience with administration to patients with a Child-Pugh score greater than 9. Do not administer rosuvastatin to patients with active liver disease. Race: Because systemic exposure to this medicine is increased in Asian patients, the recommended initial dose is 5 mg. Administration of the 40 mg dose is contraindicated. Patients predisposed to myopathy: The recommended initial dose for patients predisposed to myopathy is 5 mg. Administration of rosuvastatin 40 mg is contraindicated in some of these patients.
Child dose
The safety and efficacy of this medicine have not been established in pediatric and adolescent patients aged 18 years or younger.

Ingredients

Manufacturer
Boryung Pharmaceutical Co., Ltd.

Efficacy & effects

Treatment of hypertension; improvement of dyslipidemia; reduction of atherosclerosis progression and cardiovascular disease risk

  • Essential hypertension
  • primary hypercholesterolemia
  • heterozygous familial hypercholesterolemia
  • mixed dyslipidemia
  • homozygous familial hypercholesterolemia
  • hypercholesterolemia
  • primary dysbetalipoproteinemia
  • coronary artery disease
  • increased high-sensitivity C-reactive protein
  • hypertension
  • low HDL cholesterol levels
  • smoking
View approved original text

This medication is used for patients with essential hypertension that is not well controlled with Pimasartan and Amlodipine combination therapy. Rosuvastatin also helps in improving various types of hypercholesterolemia and dyslipidemia. When not controlled by diet and exercise, it is administered as an adjunctive therapy and is effective in reducing the risk of cardiovascular diseases. In particular, by lowering cholesterol levels, it slows the progression of atherosclerosis and reduces the risk of complications following stroke, myocardial infarction, and arterial revascularization. Therefore, this medication is used to improve cardiovascular health through blood pressure and blood lipid management.

How to take

Adult dose

Take 1 tablet once daily with water, regardless of meals. If possible, it is recommended to take it at the same time each day (e.g., in the morning). This medicine is for adults only. The dose should be individualized for each patient based on the efficacy and tolerability of the fimasartan/amlodipine combination and rosuvastatin. Patients taking the fimasartan/amlodipine combination together with rosuvastatin as a single-ingredient product may switch to this medicine (a combination product containing the same amounts of each active ingredient) for convenience. Before starting the fimasartan/amlodipine combination, it is recommended that the dose be adjusted using fimasartan. However, if blood pressure is not controlled as described below, switching directly to this medicine may be considered. ㆍ 30/5 mg: For patients whose blood pressure is not adequately controlled with fimasartan 30 mg monotherapy. ㆍ 30/10 mg: For patients whose blood pressure is not adequately controlled with fimasartan 30 mg monotherapy or 30/5 mg. ㆍ 60/5 mg: For patients whose blood pressure is not adequately controlled with fimasartan 60 mg monotherapy. ㆍ 60/10 mg: For patients whose blood pressure is not adequately controlled with fimasartan 60 mg monotherapy or 60/5 mg. Elderly patients No initial dose adjustment is required in elderly patients aged 70 years or younger. In patients aged 75 years or older, amlodipine clearance is reduced; therefore, treatment should be started at a lower dose, and the dose should be increased gradually. Patients with renal impairment No dose adjustment is required in patients with mild or moderate renal impairment (creatinine clearance 30 ~ 80 mL/min). However, in patients with severe renal impairment (creatinine clearance < 30 mL/min), treatment should be initiated with fimasartan 30 mg in this medicine. Patients with hepatic impairment No dose adjustment is required in patients with mild hepatic impairment. This medicine should not be administered to patients with moderate ~ severe hepatic impairment. Primary hypercholesterolemia (type IIa, including heterozygous familial hypercholesterolemia), mixed dyslipidemia (type IIb), primary dysbetalipoproteinemia (type III), and homozygous familial hypercholesterolemia Patients receiving rosuvastatin should follow a standard cholesterol-lowering diet before and during treatment and continue it throughout the treatment period. Rosuvastatin may be taken at any time of day, regardless of meals. The initial dose is 5 mg once daily. If a greater reduction in LDL cholesterol is required, the dose may be adjusted to the maintenance dose. The maintenance dose is 10 mg once daily, which provides adequate control in most patients. The maintenance dose should be adjusted as appropriate at intervals of 4 weeks or more, according to LDL cholesterol levels, treatment goals, and patient response, and may be increased to a maximum of 20 mg daily. Elderly patients: No dose adjustment is required. Patients with renal impairment: No dose adjustment is required in patients with mild or moderate renal impairment. Do not administer to patients with severe renal impairment. Particular caution should be exercised when administering rosuvastatin 20mg to patients with moderate renal impairment. Patients with hepatic impairment: No increase in systemic exposure to rosuvastatin was observed in patients with a Child-Pugh score of 7 or less, but an increase was observed in patients with a Child-Pugh score of 8 or 9. Renal function testing should be considered in these patients. There is no experience with administration to patients with a Child-Pugh score greater than 9. Do not administer rosuvastatin to patients with active liver disease. Race: Because systemic exposure to this medicine is increased in Asian patients, the recommended initial dose is 5 mg. Administration of the 40 mg dose is contraindicated. Patients predisposed to myopathy: The recommended initial dose for patients predisposed to myopathy is 5 mg. Administration of rosuvastatin 40 mg is contraindicated in some of these patients.

Child dose

The safety and efficacy of this medicine have not been established in pediatric and adolescent patients aged 18 years or younger.

Precautions

This medication can cause serious harm or death to the fetus and newborn if taken during pregnancy, especially during the second and third trimesters, so it should be discontinued immediately upon confirmation of pregnancy. Individuals with allergies to any ingredients in this medication, pregnant or breastfeeding women, or women with the potential for pregnancy should not take this medication. Particularly, women of childbearing age not using appropriate contraception should consult a doctor before taking this medication. Patients with moderate to severe liver dysfunction, obstructive biliary disease, muscle disorders, or severely impaired kidney function should not take this medication. Patients with reduced blood volume or sodium levels, impaired kidney function, renovascular hypertension, aortic or mitral stenosis, severe hypotension, and elderly patients should take this medication carefully and have their condition closely monitored during treatment. This medication can cause serious muscle adverse reactions such as myalgia, myopathy, and rarely rhabdomyolysis, so patients should notify their doctor immediately if they experience any pain or weakness in the muscles. The Pimasartan component can increase potassium levels, so patients at risk of hyperkalemia should have their potassium levels checked regularly. This medication can affect liver function, so individuals with a history of liver disease or abnormal liver function tests should consult a doctor before taking it, and liver function tests may be necessary during treatment. Blood pressure may drop too low, so individuals experiencing symptoms of hypotension (such as dizziness or fainting) should notify healthcare providers immediately. This medication may interact with other drugs, so patients currently taking any other medications must inform their doctor or pharmacist. Pregnant or breastfeeding individuals should not take this medication, and breastfeeding women should discontinue nursing if they take it. This medication is not recommended for use in children under 18 years of age due to lack of established safety and efficacy. Elderly individuals may be more sensitive to this medication, requiring careful dosage adjustments and monitoring during treatment. In case of overdose, symptoms may include hypotension, cardiac abnormalities, and liver function abnormalities; seek appropriate treatment immediately. Dizziness may occur during driving or operating machinery while taking this medication, so caution is advised. Keep this medication out of reach of children and do not transfer it to another container.

Side effects

nausea

Not everyone experiences these, and they can vary from person to person.

Storage

Store this medication in a tightly sealed container to protect it from air and moisture. It is important to maintain storage temperatures between 1 and 30 degrees Celsius to ensure the medication's effectiveness.

Appearance and packaging

Appearance

Orange pentagonal film-coated tablet

Package unit

30 tablets/box [10 tablets/PTP*3]

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.